Home » Clinical Trials » Therapeutic Areas

Therapeutic Areas: Neurology
Disease Category: Autonomic Nervous System
Location: United States, WA

Clinical Trial Details


Research Study Summary

RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa thErapy

This is a multi-site, placebo-controlled, double-blind, randomized-withdrawal study evaluating the durability of clinical benefit of a study drug for patients with symptomatic neurogenic orthostatic hypotension. This study has a duration of up to 36 weeks, consisting of 5 periods:
  1. Screening Period: up to 4 weeks duration;
  2. Open-Label Titration Period (Titration Period): up to 4 weeks duration;
  3. Open-Label Treatment Period (Open-Label Period): 12 weeks duration;
  4. Double-Blind Treatment Period (Double-Blind Period): 12 weeks duration;
  5. Safety Follow-Up Period: 4 weeks duration.
    To Learn more

    CW ID: 224113
    Date Last Changed: April 12, 2017

Clinical Trial Snapshot

Both Male and Female
18 and up
Overall Status
Lead Sponsor
Lundbeck NA, Ltd.
36 Weeks
Facility Type
Up to $50


Inclusion Criteria:
  • 18 years or older and able to stand (with or without limited assistance)
  • Clinical diagnosis of symptomatic orthostatic hypotension associated with Primary Autonomic Failure (PD, MSA or PAF) or NDAN or DBH Deficiency
  • Score of at least 4 or greater on Orthostatic Hypotension Symptom Assessment (OHSA) Item #1 (measured at Screening [Visit 1] and the first Titration Visit [Visit 2a] prior to dosing)
  • A documented drop of at least 20 millimeters of mercury (mmHg) in SBP, within 3 minutes of standing. This can either be documented in the patient history or assessed during Screening prior to the first Titration Visit (Visit 2a)
  • Additional inclusion criteria for patients taking prescribed droxidopa prior to study entry:
  • Patients who are taking prescribed droxidopa therapy are eligible to participate in the study if they meet the other inclusion criteria and also have been on a stable dose of prescribed droxidopa for at least 2 weeks prior to the Screening Visit (Visit 1). In addition, they must meet either of the following at the Screening Visit (Visit 1):
  • The patient's Visit 1 OHSA Item #1 score is ≥ 7 AND the prescribed dose is ≤ 300 mg three times daily (TID); OR
  • The patient's Visit 1 OHSA Item #1 score is ≤6 AND worsens by ≥ 2 units when retested after washing out of droxidopa for at least 3 days.
Exclusion Criteria:
  • In the investigator's opinion, the patient is not able to understand or cooperate with study procedures
  • Known or suspected alcohol or substance use disorder within the past 12 months (DSM-5 criteria)
  • Women who are pregnant or breastfeeding
  • Women of childbearing potential (WOCP) who are not using at least one method of contraception with their partner
  • Sustained supine hypertension greater than or equal to 180 mmHg systolic or 110 mmHg diastolic. Sustained is defined as the average of 3 observations each at least 10 minutes apart with the patient having been supine and at rest for at least 5 minutes prior to each measurement.
  • Untreated closed angle glaucoma
  • Diagnosis of hypertension that requires treatment with antihypertensive medications (short-acting antihypertensives to treat nocturnal supine hypertension are allowed in this study)
  • Any significant uncontrolled cardiac arrhythmia
  • History of myocardial infarction, within the past 2 years
  • Current unstable angina
  • Congestive heart failure (NYHA Class 3 or 4)
  • Diabetic autonomic neuropathy

*Additional protocol defined inclusion and exclusion criteria do apply.

More Info

For more information, contact EvergreenHealth Research Program at 425-899-5385 or EvergreenResearch@evergreenhealth.com and ask about the RESTORE study.


EvergreenHealth Research Program
12039 NE 128th Street, Suite 300
Kirkland, WA 98034
Phone: 425-899-5385

View Map

Research Center Information:

EvergreenHealth Research Program

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.